Catalyst PharmaceuticalCPRX
CPRX
About: Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers three drug products, FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone).
Employees: 167
0
Funds holding %
of 7,419 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
98% more call options, than puts
Call options by funds: $490K | Put options by funds: $248K
71% more first-time investments, than exits
New positions opened: 60 | Existing positions closed: 35
56% more repeat investments, than reductions
Existing positions increased: 140 | Existing positions reduced: 90
7% more capital invested
Capital invested by funds: $1.89B [Q3] → $2.04B (+$141M) [Q4]
7% more funds holding
Funds holding: 312 [Q3] → 333 (+21) [Q4]
1.47% more ownership
Funds ownership: 80.27% [Q3] → 81.74% (+1.47%) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 3 [Q3] → 3 (+0) [Q4]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$32
45%
upside
Avg. target
$33
51%
upside
High target
$35
59%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
Baird Joel Beatty 18% 1-year accuracy 7 / 38 met price target | 45%upside $32 | Outperform Maintained | 3 Mar 2025 |
HC Wainwright & Co. Andrew Fein 27% 1-year accuracy 95 / 352 met price target | 59%upside $35 | Buy Reiterated | 28 Feb 2025 |
Stephens & Co. Sudan Loganathan 15% 1-year accuracy 4 / 27 met price target | 50%upside $33 | Overweight Reiterated | 27 Feb 2025 |
Financial journalist opinion
Based on 7 articles about CPRX published over the past 30 days
Neutral
GlobeNewsWire
1 week ago
Catalyst Pharmaceuticals Announces Health Canada's Acceptance of AGAMREE® New Drug Submission with Priority Review for Sub-Licensee Kye Pharmaceuticals
CORAL GABLES, Fla., April 08, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today reported that its sub-licensee in Canada, Kye Pharmaceuticals, Inc. (Kye), has announced that Health Canada has accepted the New Drug Submission (NDS) for AGAMREE®, a novel corticosteroid treatment for Duchenne muscular dystrophy (DMD), for review. The submission has been granted Priority Review, expediting the regulatory process with the potential for marketing authorization before the end of 2025. If approved, AGAMREE would be the first and only treatment option indicated for patients diagnosed with DMD in Canada.
Negative
The Motley Fool
2 weeks ago
Why a Clutch of Pharmaceutical and Biotech Stocks Escaped the Market's Swoon on Thursday
As predicted by many analysts, economists, and investors, the sweeping tariffs announced by the Trump administration on Wednesday decimated the stock market on Thursday. It had one of its worst trading days in years, and almost no sector of the economy was spared.
Positive
Zacks Investment Research
3 weeks ago
Catalyst (CPRX) Up 14.7% Since Last Earnings Report: Can It Continue?
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock?
Positive
Investors Business Daily
3 weeks ago
Catalyst Pharma Battles To All-Time High After Huge Patent Lawsuit Win
This IBD 50 holding holds top notch ratings amid a market downturn. The post Catalyst Pharma Battles To All-Time High After Huge Patent Lawsuit Win appeared first on Investor's Business Daily.
Positive
FXEmpire
3 weeks ago
Strong Revenue, Drug Performance Lift Catalyst Shares
Big Money continues buying Catalyst Pharmaceuticals, Inc. (CPRX).
Positive
Zacks Investment Research
3 weeks ago
Catalyst (CPRX) Surges 6.2%: Is This an Indication of Further Gains?
Catalyst (CPRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Positive
Seeking Alpha
1 month ago
Catalyst Pharmaceuticals: Undervalued Future With Multiple Upside Catalysts
Catalyst Pharmaceuticals' current stock price only assumes historical momentum for existing drug portfolio continues, undervaluing future upside potentials. CPRX stock's upside potential is driven by expanding drug distribution, increasing dosages, and acquiring additional drugs, while downside risk is limited by strong cash flow and exclusivity runways. The base case is very realistic, offering an attractive asymmetric trade payoff with a potential 40% upside, despite risks associated with acquisition-dependent revenue growth.
Neutral
GlobeNewsWire
1 month ago
Catalyst Pharmaceuticals to Participate in the Barclays 27th Annual Global Healthcare Conference
CORAL GABLES, Fla., March 04, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Richard J. Daly, President and CEO of Catalyst, along with other members of Catalyst's management team, will participate in the upcoming Barclays 27th Annual Global Healthcare Conference on Tuesday, March 11, 2025 being held in Miami, Florida.
Positive
Seeking Alpha
1 month ago
Catalyst Pharmaceuticals: Stable Firdapse, Promising Agamree, Fycompa Challenges
Firdapse drives Catalyst Pharmaceuticals, Inc.'s revenue with a 37% CAGR since its 2019 launch, boosted by an FDA-approved 100 mg dose expansion. Agamree targets DMD and has so far generated $46 million in its first 10 months, which does attest to its strong growth potential. However, Fycompa still faces generic competition starting May 2025. So it remains to be seen if they'll achieve a “managed and gradual” revenue decline.
Positive
The Motley Fool
1 month ago
Here's What's Driving Catalyst Pharmaceuticals Stock 8% Higher Today
Shares of drugmaker Catalyst Pharmaceuticals (CPRX 5.54%) are up a little more than 8% as of midday on Thursday, down slightly from an intraday peak gain of nearly 13%. The company's fourth-quarter results posted after Wednesday's close were markedly better than expected.
Charts implemented using Lightweight Charts™